CORE--CLINICAL

核心--临床

• 批准号: 7309663
• 负责人: ELAINE R. PESKIND
• 金额: $ 48.78万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7309663
• 关键词: Alzheimer' s disease; biomedical facility; cognition disorders; dementia; disease /disorder onset; human subject; patient /disease registry; patient oriented research

With the dramatic expansion and increased methodological sophistication in neurodegenerative dementia research, demands on the Clinical Core for clearly defined samples of persons with AD and related dementias, mild cognitive impairment (MCI), Lewy body spectrum disease, and age-matched controls have become more complex. A sample of subjects appropriate for one type of investigation (such as a clinical treatment outcome trial) is often not appropriate for other types of studies (for example, a case-control epidemiologic study or genetic linkage analysis). Still other types of samples are needed for training clinicians to manage the multiple clinical problems expressed during the course of dementia. To meet these multiple demands, the Clinical Core has developed and will continue to provide multiple samples of AD patients, non-AD dementia patients, MCI, and normal healthy control subjects suitable for supporting the subject recruitment needs of a broad range of research and clinical training in neurodegenerative dementias. The Clinical Core will continue to include probable AD and nondemented older controls selected for maximum appropriateness for participation in clinical studies. To comply with NIA guidance to focus on earlier stages of AD and the transition from normal aging, we will focus on increasing subject samples with early AD, MCI, and cognitively normal older controls. In addition, subjects with non-AD neurodegenerative dementing disorders and Lewy body spectrum disease will be recruited and followed in the Clinical Core. Clinical Core personnel support and interact with population-based cohorts of late life dementia and normal control subjects appropriate for epidemiologic studies and which provide additional sources for accession of postmortem brain tissue. Clinical Core personnel will continue to collect cerebrospinal fluid (CSF), plasma and serum on these subject samples and through collaborative efforts with multiple ADCs, continue to expand the large UW ADRC CSF bank to support the search for biomarkers for diagnosis and monitoring disease progression of dementing disorders. Through all these subject populations, subjects, biological fluid samples, and data are provided to meet the research needs of ADRC investigators, other appropriate investigators in the broader University of Washington research community, and investigators at other institutions.

随着神经退行性痴呆症研究中的急剧扩张和方法学的复杂性，对临床核心的需求对明确定义的AD和相关痴呆症患者的样本，轻度认知障碍（MCI），Lewy体谱疾病以及年龄匹配的对照变得更加复杂。适合一种研究的受试者样本（例如临床治疗结果试验）通常不适合其他类型的研究（例如，病例对照流行病学研究或遗传联系分析）。仍需要其他类型的样本才能培训临床医生来管理痴呆症过程中表达的多个临床问题。为了满足这些多种要求， 临床核心已开发并将继续提供多种AD患者，非AD痴呆症患者，MCI和正常健康对照受试者的样本，适合于支持神经退行性痴呆症的广泛研究和临床培训的受试者需求。临床核心将继续包括可能的AD和无需选择的旧对照，以最大程度地适当地参与临床研究。为了遵守NIA的指导，专注于AD的早期阶段以及从正常衰老的过渡，我们将专注于通过早期AD，MCI和认知正常的正常旧对照来增加受试者样本。此外，将在临床核心中招募非AD神经退行性痴呆障碍和Lewy体谱疾病的受试者。临床核心人员 支持并与适合流行病学研究的晚期痴呆症和正常对照受试者的基于人群的同类群体相互作用，并为康复后脑组织提供了其他来源。临床核心人员将继续在这些主题样本上收集脑脊液（CSF），血浆和血清，并通过与多个ADC的协作努力，继续扩展大型UW ADRC CSF银行，以支持寻找生物标志物，以寻求诊断和监测摄取疾病进展的生物标志物。通过所有这些受试者，受试者，生物流体样本和数据是 提供的目的是满足ADRC调查人员，华盛顿大学更广泛的研究人员的其他适当研究人员以及其他机构的研究人员的研究需求。